Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Immune checkpoint inhibitors (CPIs) emerged as an effective and safe therapeutic option for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients lose their response to CPIs. To improve outcomes in this setting, two strategies can be considered: salvage chemotherapy (CHT) for those with an unsatisfactory response, and autologous stem-cell transplantation (auto-SCT) as a consolidation for patients with at least partial response (PR).We analyzed retrospectively the effectiveness in terms of rate of response and survivals of these two approaches in cohort 1 (salvage CHT) and in cohort 2 (auto-SCT consolidation). Adverse events were also assessed.A total of 45 heavily pre-treated patients were analyzed (median of 4 prior therapies; 93.3% refractory to the last therapy). Thirty patients received further CHT at a median of 32 days (range 1-1213) after CPI Fifteen patients in cohort 2 underwent auto-SCT, with 8 in complete response (CR) and 7 in PR. In cohort 1 a final overall response rate (ORR) of 50.0% with a median progression-free survival of 24.6 months. In cohort 2, the ORR was 93.3% (all CR) with median survivals not reached. No unexpected or cumulative toxicities were observed.Our findings suggest that auto-SCT is an effective consolidation strategy for cHL patients who achieve at least a PR after CPI therapy, despite multiple prior lines of treatment. Additionally, CPIs treatment appears to sensitize heavily pre-treated and chemorefractory patients to subsequent chemotherapy, potentially facilitating successful transplant consolidation and improving the chances of cure.